Biomarker discovery using NUcleic Acid-Linked Immuno-Sandwich Assay in multiple sclerosis patients experiencing
Sofia Sandgren1,2, Aleksandra Maleska Maceski3, Pascal Benkert3
1Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Background/Objectives:
This cohort study aimed to identify blood-based biomarkers associated with progression independent of relapse activity (PIRA) in persons with multiple sclerosis (pwMS) using the multiplex NUcleic Acid-Linked Immuno-Sandwich Assay (NULISA).
Methods:
NULISA 'CNS Disease Panel' and 'Inflammation Panel' were applied on plasma samples from pwMS following B cell-depleting therapy (BCDT; n = 185) or fingolimod (n = 200), median follow-up 4.0 (BCDT) and 9.1 (fingolimod) years. Plasma NULISA results (322 unique proteins; 0.9 and 1 year after treatment start, respectively) were investigated for their potential to prognosticate PIRA.
Results:
'CNS Disease Panel' derived glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) were identified as predictive of PIRA by multivariable Cox regression models (GFAP: BCDT: hazard ratio (HR) = 1.79, 95% confidence interval (CI) = 1.26-2.55, p = 0.0011; fingolimod: HR = 1.73, 95% CI = 1.14-2.64, p = 0.0104; NfL: BCDT: HR = 1.99, 95% CI = 1.31-3.02, p = 0.0013). GFAP derived from the 'Inflammation Panel' exhibited patterns like those observed with 'CNS Disease Panel' derived GFAP. Beyond GFAP and NfL, 12 biomarker candidates predictive of PIRA were identified. No target passed multiple test corrections, but GFAP consistently showed the highest hazard.
Conclusion:
Among over 300 proteins investigated by NULISA, GFAP was the main biomarker significantly associated with future PIRA risk in our cohort.
More Related Videos
11:35Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay EMSA and DNA-affinity Precipitation Assay DAPA
Published on: August 21, 2016
06:19Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022